Compare MIRM & AGM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MIRM | AGM |
|---|---|---|
| Founded | 2018 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 1.7B |
| IPO Year | 2019 | N/A |
| Metric | MIRM | AGM |
|---|---|---|
| Price | $65.07 | $182.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 1 |
| Target Price | $87.55 | ★ $219.00 |
| AVG Volume (30 Days) | ★ 545.4K | 81.1K |
| Earning Date | 11-04-2025 | 11-03-2025 |
| Dividend Yield | N/A | ★ 3.25% |
| EPS Growth | N/A | ★ 12.85 |
| EPS | N/A | ★ 17.55 |
| Revenue | ★ $471,794,000.00 | $377,946,000.00 |
| Revenue This Year | $53.78 | $14.80 |
| Revenue Next Year | $19.91 | $9.98 |
| P/E Ratio | ★ N/A | $10.52 |
| Revenue Growth | ★ 53.66 | 8.81 |
| 52 Week Low | $36.88 | $155.00 |
| 52 Week High | $78.55 | $216.35 |
| Indicator | MIRM | AGM |
|---|---|---|
| Relative Strength Index (RSI) | 36.47 | 69.06 |
| Support Level | $63.66 | $173.59 |
| Resistance Level | $66.77 | $186.64 |
| Average True Range (ATR) | 2.99 | 4.35 |
| MACD | -0.66 | 1.31 |
| Stochastic Oscillator | 13.68 | 85.65 |
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Federal Agricultural Mortgage Corp provides agricultural real estate and rural housing mortgage loans in the secondary market in the U.S. Its operations consist of seven segments: Farm & Ranch, Corporate AgFinance, Power & Utilities, Broadband Infrastructure, Renewable Energy, Funding, and Investments. The company purchases eligible mortgage loans secured by first liens on agricultural real estate and rural housing under the Farm & Ranch line of business. Its subsidiary purchases portions of certain agricultural, rural development, business and industry, and community facilities loans guaranteed by the USDA.